To bring closer the families with DUPLICATION which is Rare-most of all DMD mutations.
Location: New Delhi, India
Latest Activity: Feb 13, 2017
Started by kathy mcdonald. Last reply by Char Burke May 30, 2011.
Started by Char Burke. Last reply by kathy mcdonald May 24, 2011.
My Nephew age is 7.5 years.
Thanks for answer,I'm already a member this group. I have a question in my mind. My son is 5 years old. And his doctor started prednisolen 6 month ago. Another an endocrine doctor we have, He told us that my son has thyroid resistance already so, if we give to him cortisone without treatment thyroid resistance, Prednisolen is not enough and effective for him .
The use of cortisone, thyroid function more breaks......On the contrary, according to my oppinion; This is a vicious circle..
Question is; Immediately after the start of treatment with cortisone, İs there any boy who is diagnosed with thyroid resistance?
I had emailed Sharon Hesterlee about duplications and specifically personalized medicine re duplications. She said that I could share the email so I thought I would. Here you go.
It might be possible to address duplications (small ones) with exon skipping--Steve Wilton is working on that now in his laboratory. There is also a new technology that might allow us to chop out large pieces of the dystrophin gene that include duplications and replace those pieces with normal dystrophin sequence--I met with a company that is developing this technology called Precision Biosciences when I was at the Biotechnology Industry Organization meeting last month. We will likely invite them to apply for an exploratory grant to see what they can do with the dystrophin gene--this approach would actually be a permanent correction since they correct the gene itself, not the RNA message like in exon-skipping.
Beyond the specific approaches there are a large number of therapeutic approaches that are not mutation-specific that would be applicable to duplications including gene therapy, blocking myostatin, upregulating IGF-1, upregulating utrophin, using cardiac drugs like spironolactone very early (evidence now shows you get skeletal muscle benefit and cardiac benefit in mice started very early on these drugs--losartan and cialis could be in that category as well). At the scientific meeting we had before the main Connect Conference this year we also discussed using arthritis drugs like remicade and some cancer drugs that have looked promising in the mdx mouse.
So none of these approaches (including exon-skipping) are likely to be a complete home run. It's very likely that we will end up using a cocktail of drugs to get the best effects--much in the same way cancer or AIDS is treated. I guess my point is that you don't have to pin your hopes on a specific therapy to address duplications--there are really only a few things in development that WON'T address duplications (exon-skipping, ataluren). Almost everything else will. Does help answer your question? Also, fee free to post this on the duplications list if you think it's helpful.
I've been involved in other discussion groups but just recently stumbled on this one. Would love to chat about anything you may know.
Welcome toPPMD Community
Sign Upor Sign In
Or sign in with:
Need help using this community site? Visit Ning's Help Page.
Terms of Service
© 2019 Created by PPMD.
Report an Issue |
Terms of Service
Please check your browser settings or contact your system administrator.